Cite
Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas.
MLA
Long, Zuoyao, et al. “Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas.” Cancers, vol. 15, no. 3, Feb. 2023, p. 700. EBSCOhost, https://doi.org/10.3390/cancers15030700.
APA
Long, Z., Lu, Y., Li, M., Fu, Z., Akbar, Y., Li, J., Chen, G., Zhang, H.-M., Wang, Q., Xiang, L., & Wang, Z. (2023). Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas. Cancers, 15(3), 700. https://doi.org/10.3390/cancers15030700
Chicago
Long, Zuoyao, Yajie Lu, Minghui Li, Zhanli Fu, Yunus Akbar, Jing Li, Guojing Chen, et al. 2023. “Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas.” Cancers 15 (3): 700. doi:10.3390/cancers15030700.